FDA Breakthrough Status for Lilly’s Sofetabart Mipitecan ADC
Indianapolis, January 20, 2026 — Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has...
oncology pipeline
Advertisement
FDA Grants Priority Review to AstraZeneca’s Baxdrostat NDA for Hard-to-Control Hypertension
Cambridge, UK & Wilmington, Delaware, December 2025 — AstraZeneca has announced that the U.S. Food and Drug Administration has...
Formosa Licenses Ophthalmic Clobetasol Suspension to Rxilient for Asia Commercialization
Taipei, Taiwan, December 2025 — Formosa Pharmaceuticals has announced a licensing agreement with Rxilient Biotech to commercialize clobetasol propionate...
Kazia Therapeutics Secures $50M Private Placement to Strengthen Pipeline Funding
Sydney, Australia, December 3, 2025 — Kazia Therapeutics has announced the pricing of a US $50 million private placement...
Innovent Biologics Joins Hang Seng Index, Marking Biopharma Breakthrough
SuZhou, China – Nov. 24, 2025 — Innovent Biologics (01801.HK), a leading Chinese biopharmaceutical company focused on oncology, cardiovascular/metabolic,...
Advertisements
HOOKIPA Completes Sale of HBV and HIV Programs to Gilead Sciences
NEW YORK and VIENNA – October 31, 2025 — HOOKIPA Pharma Inc. (OTC: HOOK) announced the completion of the...
FDA Grants Orphan Drug Designation to Utidelone for Pancreatic Cancer
SAN FRANCISCO, Sept. 25, 2025 — Biostar Pharma’s core anticancer drug Utidelone has been granted Orphan Drug Designation (ODD)...
Advertisement
